SFA
SGYP

Staton Financial Advisors’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Staton Financial Advisors’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$58K Buy
+13,000
New +$53.6K 0.05% 43

Other funds holding SGYP

PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Staton Financial Advisors's SGYP Position: Q2 2017 in Review

Staton Financial Advisors opened a new position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q2 2017: 13,000 shares worth $58K. The stake represents 0.05% of the portfolio and ranks #43 among its holdings.

146 funds tracked by Wall St. Rank hold SGYP as of Q2 2017.

  • Staton Financial Advisors held 13,000 shares of Synergy Pharmaceuticals, Inc Common Stock worth $58K as of Q2 2017.
  • Synergy Pharmaceuticals, Inc Common Stock was a new Staton Financial Advisors position in Q2 2017.
  • Synergy Pharmaceuticals, Inc Common Stock made up 0.05% of Staton Financial Advisors's portfolio in Q2 2017, its #43 holding.
  • 146 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q2 2017.

Based on Staton Financial Advisors's 13F filing for Q2 2017, filed 27 Jul 2017.